A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-12-20
AEs
3
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 13); relationship: not assessed; serious criteria: hospitalization
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 40); relationship: N
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-02 (study day 55); relationship: not assessed
Data queries
No data queries.